Assessment of normal tissue complications following prostate cancer irradiation: Comparison of radiation treatment modalities using NTCP models

Medical Physics

Volumn 37, Issue 9, 2010, Pages 5126-5137

  Takam, Rungdham ^a,b   Bezak, Eva ^a,b   Yeoh, Eric E ^a,b   Marcu, Loredana ^c  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b ROYAL ADELAIDE HOSPITAL   (Australia)

^c UNIVERSITY OF ORADEA   (Romania)

Author keywords

NTCP models; prostate radiotherapy

Indexed keywords

CHEMORADIOTHERAPY; DISEASES; DOSIMETRY; HISTOLOGY; ONCOLOGY; TISSUE; TISSUE ENGINEERING; UROLOGY;

BIOLOGICAL EFFECTIVE DOSE; FRACTIONATION SCHEDULES; HIGH-DOSE-RATE BRACHYTHERAPY; LOW DOSE RATE BRACHYTHERAPY; NORMAL TISSUE COMPLICATION PROBABILITIES; PROSTATE RADIOTHERAPY; THREE-DIMENSIONAL CONFORMAL RADIOTHERAPY (3D-CRT); TREATMENT PLANNING SYSTEMS;

RADIOTHERAPY;

BIOLOGICAL MODEL; BRACHYTHERAPY; COMPARATIVE STUDY; HUMAN; MALE; PATHOLOGY; PROBABILITY; PROSTATIC NEOPLASMS; RADIATION INJURIES;

BRACHYTHERAPY; HUMANS; MALE; MODELS, BIOLOGICAL; PROBABILITY; PROSTATIC NEOPLASMS; RADIATION INJURIES;

EID: 77956330104     PISSN: 00942405     EISSN: None     Source Type: Journal    
DOI: 10.1118/1.3481514     Document Type: Article

References (50)

1. J. E. Livsey, R. A. Cowan, J. P. Wylie, R. Swindell, G. Read, V. S. Khoo, and J. P. Logue, " Hypofractionated conformal radiotherapy in carcinoma of the prostate: Five-year outcome analysis.," Int. J. Radiat. Oncol., Biol., Phys. IOBPD3 0360-3016 57 (5), 1254-1259 (2003). 10.1016/S0360-3016(03)00752-1
2. P. A. Kupelian, V. V. Thakkar, D. Khuntia, C. Reddy, E. A. Klein, and A. Mahadevan, " Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Long-term outcomes.," Int. J. Radiat. Oncol., Biol., Phys. IOBPD3 0360-3016 63 (5), 1463-1468 (2005). 10.1016/j.ijrobp.2005.05.054
3. J. C. Blasko, P. D. Grimm, J. E. Sylvester, K. R. Badiozamani, D. Hoak, and W. Cavanagh, " Palladium-103 brachytherapy for prostate carcinoma.," Int. J. Radiat. Oncol., Biol., Phys. IOBPD3 0360-3016 46 (4), 839-850 (2000). 10.1016/S0360-3016(99)00499-X
4. L. Potters, C. Morgenstern, E. E. Mullen, P. Fearn, A. Jassal, and M. Kattan, " Twelve year outcomes following permanent brachytherapy in patients with clinically localized prostate cancer.," Int. J. Radiat. Oncol., Biol., Phys. IOBPD3 0360-3016 60 (1), S183-S184 (2004). 10.1016/j.ijrobp.2004.06.114
5. M. Zelefsky, D. A. Kuban, L. Levy, L. Potters, D. C. Beyer, J. C. Blasko, B. J. Moran, J. P. Ciezki, A. L. Zietman, T. Pisansky, M. Elshaikh, and E. M. Horwitz, " Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with permanent brachytherapy.," Int. J. Radiat. Oncol., Biol., Phys. IOBPD3 0360-3016 63 (3), S33-S34 (2005). 10.1016/j.ijrobp.2005.07. 062
6. R. Mark, G. Vallabhan, A. Akins, P. Anderson, M. Nair, T. Neumann, D. White, and S. Gurley, " Interstitial high dose rate (HDR) brachytherapy for early stage prostate cancer.," Int. J. Radiat. Oncol., Biol., Phys. IOBPD3 0360-3016 63 (2), S304 (2005). 10.1016/j.ijrobp.2005.07.521
7. S. Nilsson, B. J. Norlen, and A. Widmark, " A systematic overview of radiation therapy effects in prostate cancer.," Acta Oncol. (Madr) ZZZZZZ 0001-6381 43 (4), 316-381 (2004). 10.1080/02841860410030661
8. P. A. Kupelian, C. A. Reddy, T. P. Carlson, and T. R. Willoughby, " Dose/volume relationship of late rectal bleeding after external beam radiotherapy for localized prostate cancer: Absolute or relative rectal volume?," Cancer J. CAJOCB 1528-9117 8 (1), 62-66 (2002). 10.1097/00130404-200201000-00011
9. G. C. Morton, " The emerging role of high-dose-rate brachytherapy for prostate cancer.," Clin. Oncol. ZZZZZZ 0305-7399 17, 219-227 (2005). 10.1016/j.clon.2004.12.005
10. E. Panitsa, J. C. Rosenwald, and C. Kappas, " Quality control of dose volume histogram computation characteristics of 3D treatment planning systems.," Phys. Med. Biol. PHMBA7 0031-9155 43 (10), 2807-2816 (1998). 10.1088/0031-9155/43/10/010
11. A. A. Martinez, I. Pataki, G. Edmundson, E. Sebastian, D. Brabbins, and G. Gustafson, " Phase II prospective study of the use of conformal high-dose-rate brachytherapy as monotherapy for the treatment of favorable stage prostate cancer: A feasibility report.," Int. J. Radiat. Oncol., Biol., Phys. IOBPD3 0360-3016 49 (1), 61-69 (2001). 10.1016/S0360-3016(00)01463-2
12. Y. Yoshioka, T. Nose, K. Yoshida, R. -J. Oh, Y. Yamada, E. Tanaka, H. Yamazaki, T. Inoue, and T. Inoue, " High-dose-rate brachytherapy as monotherapy for localized prostate cancer: A retrospective analysis with special focus on tolerance and chronic toxicity.," Int. J. Radiat. Oncol., Biol., Phys. IOBPD3 0360-3016 56 (1), 213-220 (2003). 10.1016/S0360-3016(03)00081-6
13. I. S. Grills, A. A. Martinez, M. Hollander, R. Huang, K. Goldman, P. Y. Chen, and G. S. Gustafson, " High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds.," J. Urol. (Baltimore) JOURAA 0022-5347 171 (3), 1098-1104 (2004). 10.1097/01.ju.0000113299.34404.22
14. T. Martin, D. Baltas, R. Kurek, S. Röddiger, M. Kontova, G. Anagnostopoulos, T. Dannenberg, T. Buhleier, G. Skazikis, U. Tunn, and N. Zamboglou, " 3-D conformal HDR brachytherapy as monotherapy for localized prostate cancer.," Strahlenther. Onkol. STONE4 0179-7158 180 (4), 225-232 (2004). 10.1007/s00066-004-1215-4
15. C. D. Springer, R. N. Boyd, T. C. Elsdon, L. S. Skeates, A. A. McKenzie, and S. Ozard, " Outcome analysis of HDR prostate brachytherapy in the management of patients with localized prostate cancer in a community cancer center.," Brachytherapy BRACC4 1538-4721 6 (2), 106 (2007). 10.1016/j.brachy.2007.02.094
16. D. J. Demanes, M. Gilhezan, L. Schour, G. Gustafson, D. R. Hill, K. Marvin, I. Bernstein, and A. A. Martinez, " High dose rate brachytherapy (HDR-BT) as monotherapy for favorable prostate cancer: Excellent 5-year control rates and low toxicity.," Int. J. Radiat. Oncol., Biol., Phys. IOBPD3 0360-3016 69 (3), S83 (2007). 10.1016/j.ijrobp.2007.07.150
17. R. G. Dale, " The application of the linear-quadratic dose-effect equation of fractionated and protracted radiotherapy.," Br. J. Radiol. BJRAAP 0007-1285 58, 515-528 (1985). 10.1259/0007-1285-58-690-515
18. R. G. Dale, " The application of the linear-quadratic model to fractionated radiotherapy when there is incomplete normal tissue recovery between fractions, and possible implications for treatments involving multiple fractions per day.," Br. J. Radiol. BJRAAP 0007-1285 59, 919-927 (1986). 10.1259/0007-1285-59-705-919
19. S. Nag and N. Gupta, " A simple method of obtaining equivalent doses for use in HDR brachytherapy.," Int. J. Radiat. Oncol., Biol., Phys. IOBPD3 0360-3016 46, 507-513 (2000). 10.1016/S0360-3016(99)00330-2
20. T. Rancati, C. Fiorino, G. Gagliardi, G. M. Cattaneo, G. Sanguineti, V. C. Borca, C. Cozzarini, G. Fellin, F. Foppiano, G. Girelli, L. Menegotti, A. Piazzolla, V. Vavassori, and R. Valdagni, " Early clinical and radiological pulmonary complications following breast cancer radiation therapy: NTCP fit with four different models.," Radiother. Oncol. RAONDT 0167-8140 82, 308-316 (2007). 10.1016/j.radonc.2006.12.001
21. G. Gagliardi, J. Bjöhle, I. Lax, A. Ottolenghi, F. Eriksson, A. Liedberg, P. Lind, and L. E. Rutqvist, " Radiation pneumonitis after breast cancer irradiation: Analysis of the complication probability using the relative seriality model.," Int. J. Radiat. Oncol., Biol., Phys. IOBPD3 0360-3016 46 (2), 373-381 (2000). 10.1016/S0360-3016(99)00420-4
22. P. Kallman, A. Agren, and A. Brahme, " Tumour and normal tissue response to fractionated non-uniform dose delivery.," Int. J. Radiat. Biol. IJRBE7 0955-3022 62 (2), 249-262 (1992). 10.1080/09553009214552071
23. R. I. MacKay, J. H. Hendry, C. J. Moore, P. C. Williams, and G. Read, " Predicting late rectal complications following prostate conformal radiotherapy using biologically effective doses and normalized dose-surface histograms.," Br. J. Radiol. BJRAAP 0007-1285 70, 517-526 (1997).
24. M. Zaider, M. J. Zelefsky, G. N. Cohen, C. -S. Chui, E. D. Yorke, L. Ben-Porat, and L. Happersett, " Methodology for biologically-based treatment planning for combined low-dose-rate (permanent implant) and high-dose-rate (fractionated) treatment of prostate cancer.," Int. J. Radiat. Oncol., Biol., Phys. IOBPD3 0360-3016 61 (3), 702-713 (2005). 10.1016/j.ijrobp.2004.06.251
25. A. Dau, I. Toma-Dau, J. Olofsson, and M. Karlsson, " The use of risk estimation models for the induction of secondary cancers following radiotherapy.," Acta Oncol. (Madr) ZZZZZZ 0001-6381 44 (4), 339-347 (2005). 10.1080/02841860510029833
26. C. Burman, G. J. Kutcher, B. Emami, and M. Goitein, " Fitting of normal tissue tolerance data to an analytic function.," Int. J. Radiat. Oncol., Biol., Phys. IOBPD3 0360-3016 21, 123-135 (1991). 10.1016/0360-3016(91) 90172-Z
27. M. Mattia, P. D. Giudice, and B. Cacciac, " IMRT optimization: Variability of solutions and its radiobiological impact.," Med. Phys. MPHYA6 0094-2405 31 (5), 1052-1060 (2004). 10.1118/1.1695650
28. A. Niemierko and M. Goitein, " Calculation of normal tissue complication probability and dose-volume histogram reduction schemes for tissues with a critical element architecture.," Radiother. Oncol. RAONDT 0167-8140 20, 166-176 (1991). 10.1016/0167-8140(91)90093-V
29. J. T. Lyman, " Complication probability as assessed from dose-volume-histogram.," Radiat. Res. RAREAE 0033-7587 104, S13-S19 (1985). 10.2307/3576626
30. G. Kutcher, C. Burman, L. Brewster, M. Goitein, and R. Mohan, " Histogram reduction method for calculating complication probabilities for three-dimensional treatment planning evaluations.," Int. J. Radiat. Oncol., Biol., Phys. IOBPD3 0360-3016 21 (1), 137-146 (1991). 10.1016/0360-3016(91) 90173-2
31. G. J. Kutcher and C. M. Burman, " Calculation of complication probability factors for non-uniform normal tissue irradiation: The effective volume method.," Int. J. Radiat. Oncol., Biol., Phys. IOBPD3 0360-3016 16 (6), 1623-1630 (1989). 10.1016/0360-3016(89)90972-3
32. J. T. Lyman and A. B. Wolbarst, " Optimization of radiation therapy, III: A method of assessing complication probabilities from dose-volume histograms.," Int. J. Radiat. Oncol., Biol., Phys. IOBPD3 0360-3016 13, 103-109 (1987). 10.1016/0360-3016(87)90266-5
33. D. J. Brenner, " Hypofractionation for prostate cancer radiotherapy-What are the issues?," Int. J. Radiat. Oncol., Biol., Phys. IOBPD3 0360-3016 57 (4), 912-914 (2003). 10.1016/S0360-3016(03)01456-1
34. A. E. Nahum, B. Movsas, E. M. Horwitz, C. C. Stobbe, and J. D. Chapman, " Incorporating clinical measurements of hypoxia into tumor local control modeling of prostate cancer: Implications for the α/Β ratio.," Int. J. Radiat. Oncol., Biol., Phys. IOBPD3 0360-3016 57 (2), 391-401 (2003). 10.1016/S0360-3016(03)00534-0
35. J. Z. Wang and X. A. Li, " Evaluation of external beam radiotherapy and brachytherapy for localized prostate cancer using equivalent uniform dose.," Med. Phys. MPHYA6 0094-2405 30 (1), 34-40 (2003). 10.1118/1.1527674
36. G. Arcangeli, B. Saracino, S. Gomellini, and M. G. Petrongari, " A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer.," Int. J. Radiat. Oncol., Biol., Phys. IOBPD3 0360-3016 78 (1), 11-18 (2010).
37. H. Lukka, C. Hayter, J. A. Julian, and P. Warde, " Randomized trial comparing two fractionation schedules for patients with localized prostate cancer.," J. Clin. Oncol. JCONDN 0732-183X 23, 6132-6138 (2005). 10.1200/JCO.2005.06.153
38. D. Norkus, " A randomized trial comparing hypofractionated and conventionally fractionated three-dimensional external-beam radiotherapy for localized prostate adenocarcinoma: A report on acute toxicity.," Strahlenther. Onkol. STONE4 0179-7158 185 (11), 715-721 (2009). 10.1007/s00066-009-1982-z
39. A. Pollack, " Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypo fractionation dose escalation trial.," Int. J. Radiat. Oncol., Biol., Phys. IOBPD3 0360-3016 64 (2), 518-526 (2006). 10.1016/j.ijrobp.2005.07.970
40. E. Yeoh, " Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: Updated results of a phase III randomized trial.," Int. J. Radiat. Oncol., Biol., Phys. IOBPD3 0360-3016 66, 1072-1083 (2006). 10.1016/j.ijrobp.2006.06.005
41. L. Astrom, D. Pedersen, C. Mercke, S. Holmang, and K. A. Johansson, " Long-term outcome of high dose rate brachytherapy in radiotherapy for localized prostate cancer.," Radiother. Oncol. RAONDT 0167-8140 74, 157-161 (2005). 10.1016/j.radonc.2004.10.014
42. R. M. Galalae, G. Kovacs, J. Schultze, T. Loch, P. Rzehak, R. Wilhelm, H. Bertermann, B. Buschbeck, P. Kohr, and B. Kimmig, " Long-term outcome after elective irradiation of the pelvic lymphatics and local dose escalation using high-dose-rate brachytherapy for locally advanced prostate cancer.," Int. J. Radiat. Oncol., Biol., Phys. IOBPD3 0360-3016 52 (1), 81-90 (2002). 10.1016/S0360-3016(01)01758-8
43. T. Akimoto, H. Katoh, S. -E. Noda, K. Ito, T. Yamamoto, B. Kashiwagi, and T. Nakano, " Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.," Int. J. Radiat. Oncol., Biol., Phys. IOBPD3 0360-3016 63 (2), 472-478 (2005). 10.1016/j.ijrobp.2005.02.015
44. T. L. McElveen, F. M. Waterman, H. Kim, and A. P. Dicker, " Factors predicting for urinary incontinence after prostate brachytherapy.," Int. J. Radiat. Oncol., Biol., Phys. IOBPD3 0360-3016 59 (5), 1395-1404 (2004). 10.1016/j.ijrobp.2004.01.050
45. S. Dinges, S. Deger, S. Koswig, D. Boehmer, D. Schnorr, T. Wiegel, S. A. Loening, M. Dietel, W. Hinkelbein, and V. Budach, " High-dose rate interstitial with external beam irradiation for localized prostate cancer-Results of a prospective trial.," Radiother. Oncol. RAONDT 0167-8140 48 (2), 197-202 (1998). 10.1016/S0167-8140(98)00054-1
46. J. Michalski, H. Gay, A. Jackson, S. Tucker, and J. Deasy, " Radiation dose-volume effects in radiation-induced rectal injury.," Int. J. Radiat. Oncol., Biol., Phys. IOBPD3 0360-3016 76 (3), S123-S129 (2010). 10.1016/j.ijrobp.2009.03.078
47. G. Borghede and H. Hedelin, " Radiotherapy of localised prostate cancer. Analysis of late treatment complications. A prospective study.," Radiother. Oncol. RAONDT 0167-8140 43 (2), 139-146 (1997). 10.1016/S0167- 8140(96)01871-3
48. E. Gershkevitsh, I. Rosenberg, P. D. Dearnaley, and K. -R. Trott, " Bone marrow doses and leukemia risk in radiotherapy of prostate cancer.," Radiother. Oncol. RAONDT 0167-8140 53, 189-197 (1999). 10.1016/S0167-8140(99) 00145-0
49. J. L. Bedford, V. S. Khoo, M. Oldham, D. P. Dearnaley, and S. Webb, " A comparison of coplanar four-field techniques for conformal radiotherapy of the prostate.," Radiother. Oncol. RAONDT 0167-8140 51, 225-235 (1999). 10.1016/S0167-8140(99)00057-2
50. G. Luxton, S. L. Hancock, and A. L. Boyer, " Dosimetry and radiobiologic model comparison of IMRT and 3D conformal radiotherapy in treatment of carcinoma of the prostate.," Int. J. Radiat. Oncol., Biol., Phys. IOBPD3 0360-3016 59 (1), 267-284 (2004). 10.1016/j.ijrobp.2004.01.024